🇺🇸 FDA
Patent

US 10980746

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

granted A61KA61K31/404A61K31/443

Quick answer

US patent 10980746 (Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/404, A61K31/443, A61K31/47, A61K31/4709